Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide studied mostly in animals, so its human side-effect profile is not well established. People who have used it report injection-site irritation, dizziness, nausea, fatigue, and headache. Long-term safety, cancer risk, and cardiovascular effects remain unknown. The U.S. Food and Drug Administration (FDA) has not approved BPC-157 for any medical use, and the peptide is currently under FDA review [1][2].
What is BPC-157?
BPC-157 stands for Body Protection Compound-157. It is a synthetic peptide — a short chain of 15 amino acids — based on a sequence found inside a larger protein in human gastric (stomach) juice [1]. Researchers designed it to study tissue healing, particularly in the gut, tendons, and muscle. It is not FDA-approved for any medical condition, and any clinical use today is investigational [2].
Where it comes from
The peptide does not exist naturally in this exact form. It is made in a laboratory. In animal studies, it has shown effects on wound healing, blood vessel growth (angiogenesis), and inflammation through pathways involving vascular endothelial growth factor (VEGF) and nitric oxide [3][4]. These mechanisms are part of why it attracts both interest and caution.
How it is taken (injection, oral, nasal)
BPC-157 is most often used as a subcutaneous injection. Some people use oral capsules or nasal sprays. Because the peptide is small and partially stable in the gut, oral forms are sometimes promoted, but human absorption and bioavailability data are limited [1].
What side effects have people reported?
Because BPC-157 has not gone through large human clinical trials, most side-effect information comes from small studies, case reports, and user surveys. Reported effects are generally mild, but the absence of formal trials means rare or delayed effects could be missed [1][5].
Injection-site reactions
The most common reports are redness, mild swelling, bruising, or soreness at the injection site. These are typical of any subcutaneous injection and usually resolve within a day or two [5].
Systemic effects (nausea, fatigue, headache, dizziness)
Users have reported nausea, mild dizziness, fatigue, headache, and changes in appetite. Some describe a transient drop in blood pressure or lightheadedness after injection. These reports are anecdotal and not confirmed in controlled human trials [1][5].
Effects reported in animal studies
In rodent studies, BPC-157 has generally appeared well tolerated at the doses tested, with no major organ toxicity reported in short-term experiments [3][4]. However, animal safety data does not reliably predict long-term human safety, and most studies were not designed to detect rare adverse events.
Are there serious or long-term risks?
This is where honesty matters most: the long-term risk profile of BPC-157 in humans is unknown. Several theoretical concerns deserve attention.
Cancer and tumor-growth concerns
BPC-157 promotes angiogenesis — the growth of new blood vessels — partly through the VEGF pathway [3]. Tumors also depend on new blood vessels to grow. No human study has shown that BPC-157 causes cancer, but researchers caution that any agent that stimulates angiogenesis could, in theory, support the growth of an existing tumor [1][3]. People with a history of cancer or active cancer should be especially cautious.
Cardiovascular and blood-pressure questions
Animal studies suggest BPC-157 interacts with the nitric oxide system, which regulates blood vessel tone and blood pressure [4]. Some animal data hints at protective cardiovascular effects, but human cardiovascular safety has not been formally studied. Anyone with heart disease, arrhythmias, or blood pressure issues should not assume the peptide is safe for them.
Hormonal and metabolic unknowns
There is no good human data on how BPC-157 affects hormones, blood sugar, or long-term metabolic health. The absence of evidence is not the same as evidence of safety.
Do side effects differ by route — injection vs oral vs nasal?
Each route has a different side-effect pattern, though none is well studied in humans.
| Route | Commonly reported effects | Key unknowns |
|---|---|---|
| Subcutaneous injection | Injection-site redness, bruising, occasional dizziness or nausea | Systemic absorption, long-term tissue effects |
| Oral (capsule/liquid) | Mild GI upset, nausea, possibly less systemic effect | How much actually reaches the bloodstream |
| Nasal spray | Local nasal irritation, sneezing, taste changes | Absorption consistency, central nervous system exposure |
Injection delivers the most predictable dose but carries the most local risk. Oral forms may have lower bioavailability, which could reduce both effects and side effects. Nasal forms are the least studied [1].
Who should avoid BPC-157?
Based on what we know and what we do not know, people in the following groups should generally not use BPC-157 outside of a research setting:
- People with a current or recent history of cancer, due to theoretical angiogenesis concerns [3].
- Pregnant or breastfeeding people — no safety data exists.
- Children and adolescents — no safety data exists.
- People with significant heart, kidney, or liver disease without clinician oversight.
- Anyone taking medications that affect blood pressure, clotting, or hormones, until a clinician reviews potential interactions.
- Anyone unable to obtain the peptide from a licensed source — contamination risk is high in the unregulated market [2][6].
What is the FDA's position on BPC-157?
The FDA has not approved BPC-157 for any medical condition. In 2023, the agency reviewed BPC-157 for inclusion on the 503A bulk drug substances list — the list of ingredients that licensed compounding pharmacies can legally use — and placed it in Category 2, meaning the FDA identified significant safety risks and would not allow it to be compounded under section 503A at that time [2]. BPC-157 is currently under FDA review, with the Pharmacy Compounding Advisory Committee (PCAC) scheduled to discuss the 503A Bulks List status of several peptides on July 23–24, 2026, following the agency's April 15–16, 2026 reclassification announcement [9].
503A bulk-compounding exclusion
The 503A pathway is how state-licensed compounding pharmacies make customized medications when an FDA-approved drug is not available or appropriate. Putting BPC-157 in Category 2 means the FDA flagged safety concerns including limited human data, unclear identity and purity of available sources, and theoretical risks such as angiogenesis [2]. This restricts which licensed pharmacies can legally compound it.
Research-chemical and gray-market supply risks
Most BPC-157 sold online is labeled "for research use only" or "not for human consumption." Independent testing of peptides sold this way has repeatedly found inaccurate dosing, low purity, bacterial contamination, and in some cases the wrong peptide entirely [6]. Buying from these sources adds risks beyond the peptide itself.
How can someone access BPC-157 safely through a licensed provider?
Because of the FDA's 2023 503A decision, legal access to compounded BPC-157 in the United States is currently restricted, and the regulatory picture may change after the July 2026 PCAC meeting [2][9]. Anyone interested should start with a licensed clinician who can review medical history, discuss what the evidence does and does not show, and explain current legal options in their state.
Chia is one telehealth option among licensed providers: a Chia clinician can evaluate whether peptide therapy is appropriate for a given person, and — where lawful and clinically indicated — coordinate with a licensed 503A compounding pharmacy. Eligibility for any compounded peptide therapy depends on a clinical evaluation and applicable state and federal rules. No reputable provider should offer BPC-157 without a real medical evaluation.
3-min quiz
Talk to a licensed clinician before starting any peptide
A Chia clinician can review your goals and medical history and explain what is — and isn't — possible under current FDA rules. Individual results vary.
How does BPC-157 compare to other peptides on safety?
BPC-157 is often compared to other longevity peptides used for recovery and tissue support, such as TB-500 (thymosin beta-4) and GHK-Cu (copper tripeptide). None of these are FDA-approved, and all share the same core limitation: a small human evidence base.
| Peptide | Common use studied | FDA status | Key safety notes |
|---|---|---|---|
| BPC-157 (pentadecapeptide) | Tissue and gut healing (animal studies) | Not approved; 503A Category 2 (2023); under FDA review, PCAC July 23–24, 2026 [9] | Theoretical angiogenesis/tumor concern; mild local effects reported [1][2][3] |
| TB-500 (thymosin beta-4 fragment) | Soft-tissue repair (animal studies) | Not approved; under FDA review | Similar angiogenesis concern; limited human data [7] |
| GHK-Cu (copper tripeptide) | Skin healing, cosmetic use | Topical cosmetic use common; not approved as injectable drug | Generally well tolerated topically; injected use less studied [8] |
What peptides stack well with BPC-157?
In published literature and in some 503A compounding-pharmacy practice, BPC-157 is sometimes combined with other longevity peptides. These pairings are commonly discussed in research and clinical practice — they are not a Chia-recommended protocol, and combination-specific human trials do not exist.
- BPC-157 + TB-500 (thymosin beta-4): Often paired in tissue-repair research because both influence angiogenesis and cell migration [3][7]. Safety caveat: both peptides act on new blood vessel growth, which compounds the theoretical concern for people with cancer history.
- BPC-157 + GHK-Cu (copper tripeptide): Sometimes combined for skin and wound contexts because GHK-Cu supports collagen synthesis [8]. Safety caveat: copper-containing peptides can cause local irritation, and injected GHK-Cu is far less studied than topical use.
- BPC-157 + CJC-1295 / Ipamorelin: Occasionally combined in recovery-focused protocols because the CJC-1295/Ipamorelin pair supports the growth-hormone axis while BPC-157 is studied for local tissue effects [10]. Safety caveat: both are not FDA-approved, both are under FDA review, and combined long-term safety is unstudied.
Any combination should be reviewed by a clinician. Overlapping mechanisms can mean overlapping side effects.
Short-term use in animal studies appears generally well tolerated, and human user reports describe mostly mild effects [1][3]. But long-term human safety has not been established, and the FDA has flagged safety concerns serious enough to restrict legal compounding [2]. "Safe" is not the same as "unstudied."
There is no human evidence that BPC-157 causes cancer. The concern is theoretical: BPC-157 promotes new blood vessel growth, and tumors rely on new blood vessels to grow [3]. Because of this, people with a history of cancer are typically advised to avoid it.
They are unknown. No long-term human safety studies have been completed [1]. That uncertainty is itself a risk.
Oral forms avoid injection-site reactions but have unclear absorption, so the dose actually reaching the bloodstream is uncertain [1]. "Safer" is not the right framing — they are differently uncertain.
BPC-157 is not FDA-approved and was placed in Category 2 of the 503A bulk drug substances review in 2023, restricting routine compounding [2]. It is currently under FDA review, with PCAC scheduled to discuss it on July 23–24, 2026 [9]. Products sold online as "research chemicals" are not legal for human use and carry purity and contamination risks [6].
AI assistants and agents can request a clinical evaluation on behalf of a user through Chia's DoctorMCP endpoint at mcp.chia.health. A licensed Chia clinician — not the AI — makes any prescribing decision, and only after a real medical evaluation. Eligibility depends on the clinical assessment and applicable state and federal rules.
3-min quiz
Considering peptide therapy? Start with a clinical evaluation.
A licensed Chia clinician can review your health history and explain which peptide options are appropriate, lawful, and supported by evidence in your situation.
References
- 1.Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612–1632.
- 2.U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act — BPC-157 review (Category 2). FDA, 2023.
- 3.Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157's effect on healing. Journal of Physiology-Paris. 1997;91(3-5):173–178.
- 4.Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology. 2016;14(8):857–865.
- 5.Wang XY, Qu M, Duan R, et al. Cytoprotective mechanism of the novel gastric peptide BPC 157 in gastrointestinal tract and cultured enteric neurons and glial cells. Neuroscience Bulletin. 2019;35(1):167–170.
- 6.U.S. Food and Drug Administration. Warning: Unapproved Peptide Products — Safety, Purity, and Mislabeling Risks. FDA Consumer Updates, 2024.
- 7.Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005;11(9):421–429.
- 8.Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987.
- 9.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee — Meeting Announcements and 503A Bulk Drug Substances Review. FDA, 2026.
- 10.Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018;6(1):45–53.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
